Use of ibuprofen and risk of Parkinson disease
Abstract
Background:
Neuroinflammation may contribute to the pathogenesis of Parkinson disease (PD). Use of nonsteroidal anti-inflammatory drugs (NSAID) in general, and possibly ibuprofen in particular, has been shown to be related to lower PD risk in previous epidemiologic studies.
Methods:
We prospectively examined whether use of ibuprofen or other NSAIDs is associated with lower PD risk among 136,197 participants in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) free of PD at baseline (1998 for NHS and 2000 for HPFS). NSAIDs use was assessed via questionnaire. Results were combined in a meta-analysis with those of published prospective investigations.
Results:
We identified 291 incident PD cases during 6 years of follow-up. Users of ibuprofen had a significantly lower PD risk than nonusers (relative risk [RR], adjusted for age, smoking, caffeine, and other covariates = 0.62; 95% confidence interval [CI] 0.42–0.93; p = 0.02). There was a dose–response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0.01). In contrast, PD risk was not significantly related to use of aspirin (RR = 0.99; 95% CI 0.78–1.26), other NSAIDs (RR = 1.26; 95% CI 0.86–1.84), or acetaminophen (RR = 0.86; 95% CI 0.62–1.18). Similar results were obtained in the meta-analyses: the pooled RR was 0.73 (95% CI 0.63–0.85; p < 0.0001) for ibuprofen use, whereas use of other types of analgesics was not associated with lower PD risk.
Conclusions:
The association between use of ibuprofen and lower PD risks, not shared by other NSAIDs or acetaminophen, suggests ibuprofen should be further investigated as a potential neuroprotective agent against PD.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
Smith PF. Inflammation in Parkinson's disease: an update. Curr Opin Investig Drugs 2008;9:478–484.
2.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–397.
3.
Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059–1064.
4.
Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005;58:963–967.
5.
Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009;26:769–779.
6.
Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010;74:995–1002.
7.
Feskanich D, Rimm EB, Giovannucci EL, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc 1993;93:790–796.
8.
Salvini S, Hunter DJ, Sampson L, et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989;18:858–867.
9.
Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56–63.
10.
Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009;65:76–82.
11.
Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology 1993;4:218–228.
12.
Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007;166:561–567.
13.
Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007;69:1696–1700.
14.
Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008;167:831–838.
15.
Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 2008;23:88–95.
16.
Etminan M, Carleton BC, Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008;15:576–577.
17.
Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836–1842.
18.
Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007;28:193–196.
19.
Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006;66:1097–1099.
20.
Ton TG, Heckbert SR, Longstreth WT, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006;21:964–969.
21.
Etminan M, Suissa S. NSAID use and the risk of Parkinson's disease. Curr Drug Saf 2006;1:223–225.
22.
Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64:576–580.
23.
Bower JH, Maraganore DM, Peterson BJ, Ahlskog JE, Rocca WA. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006;67:494–496.
24.
Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 2003;12:315–326.
25.
Iso H, Hennekens CH, Stampfer MJ, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999;30:1764–1771.
26.
Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002;40:604–608, discussion 601–603.
27.
Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007;205:295–312.
28.
Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325–340.
29.
Asanuma M, Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des 2008;14:1428–1434.
30.
Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? Exp Neurol 2007;206:172–178.
31.
Tsuji T, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N. Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen. Neurochem Res 2009;34:764–774.
32.
Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000;289:201–204.
33.
Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008;106:506–518.
34.
Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol 2006;59:988–989.
35.
Milatovic D, Zaja-Milatovic S, Montine KS, Horner PJ, Montine TJ. Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem 2003;87:1518–1526.
36.
Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008;70:1672–1677.
37.
Helmuth L. NSAIDS for prevention? Protecting the brain while killing pain? Science 2002;297:1262–1263.
38.
Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004;164:1519–1524.
39.
Williams DR, Lees AJ. How do patients with parkinsonism present? A clinicopathological study. Intern Med J 2009;39:7–12.
40.
Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 1993;43:505–508.
Information & Authors
Information
Published In
Copyright
Copyright © 2011 by AAN Enterprises, Inc.
Publication History
Received: March 6, 2010
Accepted: October 4, 2010
Published online: March 2, 2011
Published in print: March 8, 2011
Disclosure
Dr. Gao has received research support from the NIH/NINDS. Dr. Chen has received intramural funding from the NIH. Dr. Schwarzschild has received research support from the NIH/NINDS, the US Department of Defense, the Michael J. Fox Foundation, the Parkinson Disease Foundation, the RJG Parkinson's Disease Foundation, the American Parkinson Disease Association, and the American Federation for Aging Research. Dr. Ascherio serves on a scientific advisory board for the Michael J. Fox Foundation; serves on the editorial boards of Neurology®, Annals of Neurology, and the American Journal of Epidemiology; has received speaker honoraria from Merck Serono; and receives research support from the NIH, the US Department of Defense, and the Michael J. Fox Foundation.
Authors
Author Contributions
Statistical analysis was conducted by Dr. Gao.
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Neuroinflammation, glymphatic system, and Parkinson's disease, Translational Models of Parkinson' s Disease and Related Movement Disorders, (3-27), (2025).https://doi.org/10.1016/B978-0-443-16128-5.00001-3
- Neuropathology insights: Parkinson's, Alzheimer's and their nexus, Essential Guide to Neurodegenerative Disorders, (55-71), (2025).https://doi.org/10.1016/B978-0-443-15702-8.00004-X
- Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications, International Journal of Molecular Sciences, 25, 7, (3995), (2024).https://doi.org/10.3390/ijms25073995
- What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson’s Disease?, International Journal of Molecular Sciences, 25, 3, (1641), (2024).https://doi.org/10.3390/ijms25031641
- Investigating the Effect of an Anti-Inflammatory Drug in Determining NURR1 Expression and Thus Exploring the Progression of Parkinson's Disease, Physiological Research, 1/2024, (139-155), (2024).https://doi.org/10.33549/physiolres.935168
- Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents, Journal of Parkinson's Disease, 14, 7, (1283-1300), (2024).https://doi.org/10.3233/JPD-240353
- Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?, Journal of Parkinson's Disease, 14, 2, (227-244), (2024).https://doi.org/10.3233/JPD-230315
- Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond, Current Neuropharmacology, 22, 6, (1080-1109), (2024).https://doi.org/10.2174/1570159X22666231017141636
- Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease , Science Translational Medicine, 16, 761, (2024).https://doi.org/10.1126/scitranslmed.adm8563
- Spatial Arrangement of the Drug Ibuprofen in a Model Membrane in the Presence of Lipid Rafts, The Journal of Physical Chemistry B, 128, 15, (3652-3661), (2024).https://doi.org/10.1021/acs.jpcb.4c01507
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.